Last reviewed · How we verify

NCT03764267

MAC vs TIVA Ambulatory Breast Augmentation

Completed Phase 3 Last updated 5 December 2018
What this trial tests

Phase 3 trial testing Remifentanil in Breast Diseases in 80 participants. Completed in 1 January 2018.

Timeline
1 January 2014
Primary endpoint
1 January 2017
1 January 2018

Quick facts

Lead sponsorAin Shams University
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeother
Enrollment80
Start date1 January 2014
Primary completion1 January 2017
Estimated completion1 January 2018

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 21 to 50, female only, with Breast Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

hypothesis: the combination of LA with remifentanil and ketofol \[monitored anesthesia care (MAC)\] for ambulatory breast augmentation may result in results in better QoR on day of surgery as compared with total i.v. anesthesia (TIVA) . The purpose of this study was to compare the QoR after MAC using remifentanil and ketofol with TIVA during ambulatory breast augmentation .

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Remifentanil

Trials testing the same drug.

Other recruiting trials for Breast Diseases

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03764267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing